Invus Group, an equity investment firm founded in 1985 with over $8bn of evergreen capital, led a $30m financing round in Presidio Medical, a clinical-stage medical device company developing a neuromodulation platform technology. The round had participation from existing investor, Action Potential Venture Capital. The investment will be used to further develop the current technology for the treatment of chronic pain as well as to expand application of the platform to address additional indications.